Silence Therapeutics Plc (SLN) Stock Price & Analysis
Silence Therapeutics Plc (SLN) fell 3.76% to USD 11.02 as of July 26, 2026 at 08:56 UTC, according to Nexqual real-time market data.
SLN last closed at USD 11.45; the session ranged USD 10.88–11.51 on volume of 339,196 shares. Market capitalization is $520.53M, with a 52-week range of USD 4.19–11.9 (NGM). Source: Nexqual, July 26, 2026 at 08:56 UTC.
Key Statistics (as of July 26, 2026 at 08:56 UTC)
| Price | USD 11.02 |
|---|---|
| Change | ▼ 3.76% (down) |
| Previous Close | USD 11.45 |
| Open | USD 11.41 |
| Day Range | USD 10.88 – 11.51 |
| 52-Week Range | USD 4.19 – 11.9 |
| Volume | 339,196 shares |
| Market Cap | $520.53M |
| Exchange | NGM |
Technical Analysis (SLN)
Nexqual's technical model rates SLN "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 26, 2026 at 08:56 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.48 (neutral) |
| vs SMA50 | Above (USD 8.25) |
| MACD | 0.82 (positive) |
Analyst Ratings (SLN)
Wall Street analysts rate SLN "Buy" based on 6 analysts, with a mean price target of USD 29.17 (range USD 4–75), per Nexqual as of July 26, 2026 at 08:56 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 29.17 |
| High Target | USD 75 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 6 / 0 / 1 |
Earnings (SLN)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $869,210 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.33 vs est -0.09 ▼ miss |
| 2025-12-31 | USD -0.27 vs est -0.49 ▲ beat |
| 2025-09-30 | USD -0.15 vs est -0.21 ▲ beat |
| 2025-06-30 | USD -0.55 vs est -0.21 ▼ miss |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
Financials & Fundamentals (SLN)
| Total Revenue | $839,000 |
|---|---|
| Revenue Growth (YoY) | +197.20% |
| Gross Margin | +79.50% |
| Operating Margin | -3565.40% |
| Profit Margin | +0.00% |
| ROE | -92.56% |
| Debt / Equity | 0.28 |
| Current Ratio | 9.83 |
| Total Cash | $70.08M |
| Total Debt | $136,000 |
| Free Cash Flow | $-45.66M |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
Financial Health Score (SLN)
Nexqual rates Silence Therapeutics Plc's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 08:56 UTC.
| Growth | Critical — Revenue -99% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $70M cash, no debt |
| Cash Flow | Weak — FCF negative: -$46M, burning cash |
| Efficiency | Critical — ROE -93%, ROA -29.8% |
Ownership (SLN)
| Insider Ownership | +21.77% |
|---|---|
| Institutional Ownership | +44.55% |
| Shares Outstanding | 47.23M |
| Float | 27.46M |
| Short % of Float | +4.41% |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
Leadership (SLN)
Silence Therapeutics Plc is led by Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D (age 71), Interim CEO & Chairman of the Board, per Nexqual as of July 26, 2026 at 08:56 UTC.
| Interim CEO & Chairman of the Board | Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D (age 71) |
|---|---|
| Executive VP, CFO, Secretary & Executive Director | Rhonda L. Hellums (age 54) |
| Chief Scientific Officer | Marie Wikstrom Lindholm |
Major Backers & Investors (SLN)
Notable institutional backers of Silence Therapeutics Plc include TCG Crossover Management, LLC, Siren, L.L.C., Redmile Group, LLC, according to Nexqual as of July 26, 2026 at 08:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| TCG Crossover Management, LLC | 6.42% |
| Siren, L.L.C. | 6.16% |
| Redmile Group, LLC | 4.58% |
| Nantahala Capital Management, LLC | 4.54% |
| Citadel | 2.61% |
| Millennium Management | 2.27% |
| Great Point Partners LLC | 2.16% |
| Nextech Invest, Ltd. | 2.02% |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
From Silence Therapeutics Plc's Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
- The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
- It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHVS | Pharvaris N.V. | USD 34.17 | ▼ 0.55% |
| BCYC | Bicycle Therapeutics plc | USD 3.87 | ▼ 8.08% |
| KROS | Keros Therapeutics, Inc. | USD 10.06 | ▼ 1.47% |
| TRDA | Entrada Therapeutics, Inc. | USD 5.85 | ▼ 4.88% |
| IVA | Inventiva S.A. - American Depos | USD 4.46 | ▼ 1.76% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 08:56 UTC. This page is informational and not investment advice.